Phase 1 Myeloma Trial, Recruiting

Written by an AI model from the ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People aged 18 to 75 years of any gender
• People who have a confirmed diagnosis of multiple myeloma that has come back or stopped responding to treatment, and who have already received at least 3 previous treatment regimens (including at least one type from each of two specific drug classes: a proteasome inhibitor and an immunomodulatory agent)
• People whose myeloma got worse during or within 12 months after their most recent treatment, or whose myeloma got worse within the last 6 months and did not respond to the most recent treatment
• People who the treating doctor considers unable to tolerate standard treatments may also be considered
• People whose myeloma can be measured at the time of screening through specific protein levels in the blood or urine, or through certain blood markers for a particular type of myeloma
• People whose myeloma cells test positive for certain proteins called CD19 and/or BCMA (confirmed by laboratory testing of tumour tissue; previous test results may be accepted in some cases, but a new biopsy may be needed if prior treatment targeted these proteins)
• People whose side effects from previous treatments have mostly settled, with any remaining side effects being mild (Grade 1 or lower), apart from certain blood-related effects or minor issues like hair loss
• People who are reasonably well and able to carry out daily activities, as measured by a standard medical scale (ECOG score of 0, 1, or 2)

Who may not be able to join:

• People whose life expectancy is estimated to be less than 3 months
• People who have, or have had, another active cancer — though some exceptions may apply, such as certain treated skin cancers, cervical changes that have been fully treated with no recurrence for at least 3 years, locally treated prostate cancer, or certain fully surgically treated breast conditions (confirm with trial site)
• People who have had a stem cell transplant using donor cells at any time, or their own cells within the past 3 months before the planned trial treatment
• People whose myeloma is present only as a single soft tissue growth outside the bone marrow
• People diagnosed with certain related blood or plasma cell conditions, including plasma cell leukaemia, Waldenström's macroglobulinaemia, POEMS syndrome, or primary AL amyloidosis
• People who have cancer that has spread to the brain or spinal fluid, or who have symptoms suggesting this
• People who have recently received other anti-cancer treatments and whose body has not yet cleared those treatments (within 5 half-lives of that treatment before the planned trial treatment date)
• People who have an active infection that is not under control
• People who test positive for HIV, syphilis, or certain hepatitis B or C markers with detectable virus levels in the blood — though exceptions may apply if the treating doctor considers the infection preventable or controllable with medication
• People with a known active autoimmune disease that requires ongoing treatment affecting the whole body
• People with a known serious allergic reaction to the study drug or any of its ingredients
• People who are pregnant or breastfeeding
• People who have received a live vaccine within 6 weeks before enrolling in the trial

Important: Always verify eligibility with the trial site directly before applying.